e17099 Background: In metastatic hormone-sensitive prostate cancer (mHSPC), a 6-month PSA nadir ≤0.2 ng/mL is commonly applied as an early prognostic benchmark. Moreover, routine PSA reporting is often truncated at low values (e.g., 0.07 ng/mL was associated with higher risk of radiographic progression (HR 14.27; 95% CI 3.51–58.05; p 0.07 ng/mL identifies a population at imminent risk of radiographic progression. This deeper PSA response provides a pragmatic candidate threshold for assessing treatment efficacy and for risk stratification in high-volume disease, warranting validation in larger, well-designed studies. Baseline characteristics of the study population. Characteristic Overall population (n=159) Age, median (IQR), years 69.3 (63.2–74.6) ECOG performance status 0 69 (43.4%) ≥1 90 (56.6%) Metastatic status at diagnosis De novo 135 (84.9%) Recurrent 24 (15.1%) Visceral metastasis Yes 51 (32.1%) No 108 (67.9%) Charlson Comorbidity Index (CCI) Median (range) 3 (0–12) CCI <3 70 (44.0%) CCI ≥3 89 (56.0%) Baseline laboratory parameters ALP Normal Elevated 67 (42.1%)79 (49.7%) LDH Normal Elevated 68 (42.8%)72 (45.3%) PSA, median (range), ng/mL 100.5 (25.6-306.3) Systemic therapy ADT alone 39 (24.5%) ADT + ARPI 76 (47.8%) ADT + docetaxel 44 (27.7%)
Kemik et al. (Thu,) studied this question.